國家衛生研究院 NHRI:Item 3990099045/16268

NHRI > Institute of Biotechnology and Pharmaceutical Research > Shu-Yu Lin > Periodical Articles > Item 3990099045/16268

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/16268

Title:	Beta-d-Ribofuranose as a core with a phosphodiester moiety as the enzyme recognition site for codrug development
Other Titles:	β-d-Ribofuranose as a Core with a Phosphodiester Moiety as the Enzyme Recognition Site for Codrug Development
Authors:	Hwu, JR;Panja, A;Tsay, SC;Huang, WC;Lin, SY;Yeh, CS;Su, WC;Yang, LX;Shieh, DB
Contributors:	Institute of Biotechnology and Pharmaceutical Research
Abstract:	An ideal codrug design should be able to control drug release, offer selectivity during drug delivery, and break down into non-toxic fragments after biodegradation. Our design incorporates d-ribofuranose as the core, with carbamate and carbonate groups as linking joints, a phosphodiester moiety as an enzyme recognition site, and lenalidomide and paclitaxel as the constituent drugs. The codrug synthesis involves seven steps with a 33% overall yield. The target codrug increases its water solubility 685 times versus paclitaxel.
Date:	2024-11-13
Relation:	Organic letters. 2024 Nov 13;Article in Press.
Link to:	http://dx.doi.org/10.1021/acs.orglett.4c03662
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1523-7060&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:001354980900001
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85209554588
Appears in Collections:	[Shu-Yu Lin] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI001354980900001.pdf		2025Kb	Adobe PDF	16	View/Open